NIH Director Announced New NCATS Program: Discovering New Therapeutic Uses for Existing Molecules
In its pilot phase, this initiative will match researchers with more than 20 molecular compounds from Pfizer, AstraZeneca and Eli Lilly to explore how such compounds might be put to use in treating patients. For more information, see the NIH News Release and the Therapeutic Discoveries initiative RFI and NOI.